Q2 2025 Vivos Therapeutics Inc Earnings Call Transcript
Key Points
- Vivos Therapeutics Inc (VVOS) achieved a major milestone with the acquisition of The Sleep Center of Nevada, which is expected to drive future growth.
- The company reported a $500,000 uplift in sleep testing service revenue attributable to the acquisition of SCN.
- Vivos Therapeutics Inc (VVOS) has successfully deployed 1.5 new sleep optimization teams, which are expected to enhance productivity and collaboration.
- The company secured significant debt and equity financing, providing $11.5 million in net cash from financing activities.
- Initial patient demand at SCN has outpaced capacity, indicating strong market interest in Vivos Therapeutics Inc (VVOS) treatment options.
- Vivos Therapeutics Inc (VVOS) experienced a 6% decrease in revenue for the second quarter of 2025 compared to the same period in 2024.
- The company reported an operating loss of $4.9 million in the second quarter and $8.8 million for the first half of 2025.
- Cost of sales and operating expenses increased significantly due to the acquisition and integration of SCN.
- The transition and integration of SCN led to higher professional fees, personnel costs, and infrastructure expenses.
- Vivos Therapeutics Inc (VVOS) is facing constraints around physical facilities and is working to expand to meet patient demand.
Good day, everyone, and welcome to the Vivos second quarter 2025 conference call. (Operator Instructions) This conference call is being recorded, and a replay of today's call will be available on the investor relations section of Vivos website and will remain posted there for the next 30 days.
I will now hand the call over to Mr. Brad Amman, Chief Financial Officer, for introductions and the reading of the safe harbor statement. Please go ahead.
Thank you, operator. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the investor relations section of our website at www.vivos.com. With me on the call today is Kirk Huntsman, Vivos Chairman and Chief Executive Officer.
Today, we'll review the financial results for the second quarter 2025 as well as more recent developments and Vivos plans for the rest of 2025 and beyond. Following these formal remarks, we will be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
